China Biologic Products, Inc., through its indirect majority-owned subsidiary Shandong Taibang, is the only blood plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province in China with a population of 93 million. The company is engaged in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Plasma-based human albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and treatment. Wikipedia.


Time filter

Source Type

News Article | February 24, 2017
Site: marketersmedia.com

WiseGuyReports.com adds Exclusive Research on “Thromboembolism - Pipeline Review, H1 2016” reports to its database. Pune, India - February 24, 2017 /MarketersMedia/ — Thromboembolism - Pipeline Review, H1 2016 Summary The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/375988-thromboembolism-pipeline-review-h1-2016 Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope - The report provides a snapshot of the global therapeutic landscape of Thromboembolism - The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects - The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Thromboembolism Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Thromboembolism - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table of Content: Key Points Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Thromboembolism Overview 9 Therapeutics Development 10 Pipeline Products for Thromboembolism - Overview 10 Pipeline Products for Thromboembolism - Comparative Analysis 11 Thromboembolism - Therapeutics under Development by Companies 12 Thromboembolism - Therapeutics under Investigation by Universities/Institutes 13 Thromboembolism - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Thromboembolism - Products under Development by Companies 17 Thromboembolism - Products under Investigation by Universities/Institutes 18 Thromboembolism - Companies Involved in Therapeutics Development 19 Bayer AG 19 Cereno Scientific AB 20 China Biologic Products, Inc. 21 Daiichi Sankyo Company, Limited 22 F. Hoffmann-La Roche Ltd. 23 Gamma Therapeutics, Inc. 24 GlycoMimetics, Inc. 25 Green Cross Corporation 26 Ionis Pharmaceuticals, Inc. 27 Portola Pharmaceuticals, Inc. 28 …Continued ACCESS REPORT @ https://www.wiseguyreports.com/reports/375988-thromboembolism-pipeline-review-h1-2016 Get in touch: LinkedIn: www.linkedin.com/company/4828928 Twitter: https://twitter.com/WiseGuyReports Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts Contact Info:Name: Norah TrentOrganization: WiseGuy Reports Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, IndiaPhone: +1-646-845-9349 Source URL: http://marketersmedia.com/thromboembolism-pharmaceutical-and-healthcare-pipeline-review-h2/172847For more information, please visit http://www.wiseguyreports.comSource: MarketersMediaRelease ID: 172847


Browse 35 Tables and 11 Figures, 22 Companies, spread across 112 pages available at http://www.reportsnreports.com/reports/983974-hemophilia-b-pipeline-review-h1-2017.html . Hemophilia B market companies are Alnylam Pharmaceuticals Inc, Amarna Therapeutics BV, Bayer AG, Bioverativ Inc, Catalyst, Biosciences Inc, China Biologic Products Inc, CSL Ltd, Dimension Therapeutics Inc, Genethon SA, Green Cross Corp, MolMed SpA, Novo Nordisk A/S, OPKO Biologics Ltd, Pfizer Inc, Pharming Group NV, Promethera Biosciences SA, RegenxBio Inc, rEVO Biologics Inc, Sangamo Therapeutics Inc, Shire Plc, Spark Therapeutics Inc, UniQure NV. Market Hemophilia B key player's reviews involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 4, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Scope: The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders). The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The Hemophilia B market pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects and latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders). Reasons to buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ . ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


Browse 35 Tables and 11 Figures, 22 Companies, spread across 112 pages available at http://www.reportsnreports.com/reports/983974-hemophilia-b-pipeline-review-h1-2017.html . Hemophilia B market companies are Alnylam Pharmaceuticals Inc, Amarna Therapeutics BV, Bayer AG, Bioverativ Inc, Catalyst, Biosciences Inc, China Biologic Products Inc, CSL Ltd, Dimension Therapeutics Inc, Genethon SA, Green Cross Corp, MolMed SpA, Novo Nordisk A/S, OPKO Biologics Ltd, Pfizer Inc, Pharming Group NV, Promethera Biosciences SA, RegenxBio Inc, rEVO Biologics Inc, Sangamo Therapeutics Inc, Shire Plc, Spark Therapeutics Inc, UniQure NV. Market Hemophilia B key player's reviews involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 4, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Scope: The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders). The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The Hemophilia B market pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects and latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders). Reasons to buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ . ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


China Biologic will commence the mailing of the proxy statement/prospectus to all holders of China Biologic common stock as of the record date on May 19, 2017. The proposed Merger is subject to approval by holders of China Biologic common stock. China Biologic Products, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its majority owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com. For more information, please contact: This release includes forward-looking statements, including statements regarding the terms and completion of the proposed Merger, the change in the Company's place of incorporation, the ability to grow internationally and in China, the reduction in operating expenses resulting therefrom, the proposal to be approved by the Company's stockholders at the annual meeting and the commencement of the mailing of the proxy statement/prospectus. These statements are forward-looking in nature and subject to risks and uncertainties that may cause actual results to differ materially. These uncertainties include, but are not limited to, the ability of the parties to consummate the proposed Merger, the satisfaction of closing conditions to consummate the Merger, the Company's ability to realize the anticipated reduction in operating expenses, and obtaining requisite approvals, including from the Company's stockholders. All forward-looking statements included in this release are based upon information available to the Company as of the date of this release, which may change, and we assume no obligation to update any such forward-looking statement. Additional Information and Where to Find It This communication is being made in respect of a proposed redomicile transaction. INVESTORS OF CHINA BIOLOGIC ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE MAKING A DECISION CONCERNING THE PROPOSED MERGER. These documents will contain important information that investors should consider. The proxy statement/prospectus will be mailed to China Biologic stockholders. The proxy statement/ prospectus and any other documents filed by China Biologic with the SEC may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by China Biologic by contacting China Biologic's Investor Relations by phone at +86-10-6598 3177 or by email at ir@chinabiologic.com. China Biologic and its respective officers and directors may be deemed to be participants in the solicitation of proxies in connection with the proposed Merger. Information regarding the interests of these directors and executive officers in the proposed Merger, if any, is included in the proxy statement/prospectus. You can find information about China Biologic's directors and executive officers in its proxy statements and Annual Reports on Form 10-K, previously filed with the SEC. Each of these documents is available free of charge at the SEC's web site at http://www.sec.gov and from China Biologic Investor Relations. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-biologic-announces-effectiveness-of-registration-statement-and-mailing-of-definitive-proxy-statementprospectus-for-2017-annual-meeting-of-stockholders-300460666.html


China's blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 2015, estimated to reach RMB23.8 billion throughout the year, up 16.7% from 2015. China's blood product industry will develop at full speed boosted by downstream demand, accompanied by a steady rise in the number of plasma stations and consolidated profit margin improvement of plasma. The market size is expected to hit RMB47.5 billion in 2021. Main features of blood product industry in China 2016 are shown as below: 1. As plasma supply increases, supply-demand balance can be seen in 2025 China's plasma collection volume has been increasing over recent years driven by blood product price deregulation and accelerated establishment of new plasma stations. In 2016, 6,964 tons of plasma was collected in China, up 19.8% year on year. Despite continuous growth, plasma collection volume still cannot meet the ever-increasing market demand. In the future, China will see plasma collection volume shooting up propelled by a growing number of plasma collection stations and is expected to achieve balance between plasma supply and demand in 2025. 2. A steady increase in lot release volume of main products So far, Chinese blood products are still dominated by human albumin and human immunoglobulin for intravenous injection, which take an over 70% blood product market share. In 2016, human albumin and human immunoglobulin (pH4) for intravenous injection registered respective lot release volumes of 39.31 million bottles (10g/bottle) and 10.89 million bottles (2.5g/bottle), up 17.8% and 27.4% respectively year on year. In addition, lot release volumes of domestic blood products in short supply such as blood coagulation factor VIII, human immunoglobulin and human prothrombin complex also witnessed substantial growth in 2016, respectively 38.0%, 143.8% and 20%. 3. R&D efforts intensified for new products; comprehensive utilization of plasma to be raised At present, Chinese blood product enterprises can separate a maximum of 11 varieties of blood products from the plasma, 3-4 varieties for general firms, indicating an extremely low rate of comprehensive utilization of plasmas. To solve the problem, Chinese blood product enterprises are accelerating the development of new products, hoping to improve comprehensive utilization of plasma. Blood coagulation factor VIII, for example, Guizhou Taibang Biological Products Co., Ltd., Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Zhenxing Biopharmaceutical & Chemical Co., Ltd., Wuhan Zhongyuan Ruide Biological Products Co., Ltd. etc. are actively conducting clinical trials of blood coagulation factor VIII and expected to achieve mass production in next two years. 4 Plasma-oriented pattern continues Blood product industry relies heavily on plasma materials - the number of plasma stations directly influences plasma collection volume, which then affects raw material supply of blood product enterprises. Therefore, the number of plasma stations and plasma collection volume determine corporate position in industry. There are over 30 blood product manufacturing enterprises in China, but only more than 20 are able to maintain normal production. Among them, Hualan Biological Engineering,Inc., Shanghai RAAS Blood Products Co., Ltd. and China Biologic Products, Inc. boast relatively high volume of plasma collection, altogether accounting for 39.6% of total plasma collections in 2016. The report highlights the following: - Analysis on development of China blood product industry, including status quo, policy environment, market supply & demand, market size, market structure and competition pattern; - Analysis on 8 market segments of China blood product industry, including development status, competition pattern and trends; - Analysis on 13 major enterprises, including operation, blood product business, etc.; - Summary & forecast and trends. - The Chinese Version of this Report is Available on Request. 1 Overview of Truck Industry 1.1 Definition and Classification 1.2 Introduction of Technologies 1.3 Latest Policies during 2016-2017 1.3.1 Enforcement of National V Emission Standards 1.3.2 GB1589 Standards and "921 New Reform" 1.3.3 Ban on Low-Speed Trucks 1.3.4 Compulsory Installation of ABS Device for Trucks 1.3.5 Yellow Label' Vehicle Elimination Continues 1.4 Self-driving and Connected Truck 1.4.1 Truck Self-driving 1.4.2 Truck Telematics 2 Truck Market as a Whole 2.1 Ownership 2.2 Production and Sales 2.2.1 Production 2.2.2 Sales 2.3 Market Structure 2.4 Import & Export 2.5 Competitive Pattern 3 Truck Market Segments 3.1 Heavy Truck 3.1.1 Production and Sales 3.1.2 Competitive Landscape 3.1.3 Natural Gas Heavy Truck 3.1.4 High-end Heavy Truck 3.2 Medium Truck 3.2.1 Production and Sales 3.2.2 Competitive Landscape 3.3 Light Truck 3.3.1 Production and Sales 3.3.2 Competitive Landscape 3.4 Mini Truck 3.4.1 Production and Sales 3.4.2 Competitive Landscape 5 Key Companies 5.1 FAW Jiefang Automotive Co., Ltd. 5.1.1 Profile 5.1.2 Production and Sales 5.1.3 Launch of New Products 5.1.4 Manufacturing Bases 5.1.5 Developments 5.2 China National Heavy Duty Truck Group Co., Ltd. (SINOTRUK) 5.2.1 Profile 5.2.2 Operation 5.2.3 Production and Sales 5.2.4 Heavy-duty Truck Business 5.3 Dongfeng Motor Corporation 5.3.1 Profile 5.3.2 Operation 5.3.3 Truck Business 5.3.4 Capacity Distribution 5.3.5 Developments 5.4 Beiqi Foton Motor Co., Ltd. 5.4.1 Profile 5.4.2 Operation 5.4.3 Heavy-duty Truck Business 5.4.4 Production Capacity 5.4.5 Progress in Launch of New Products 5.5 Shaanxi Automobile Group Co., Ltd. 5.5.1 Profile 5.5.2 Major Products 5.5.3 Heavy-duty Truck Business 5.5.4 Developments 5.6 Anhui Jianghuai Automobile Group Corp.,Ltd. 5.6.1 Profile 5.6.2 Operation 5.6.3 Production and Sales 5.6.4 Capacity Distribution 5.6.5 Developments 5.7 Hualing Xingma Automobile (Group) Co., Ltd. 5.7.1 Profile 5.7.2 Operation 5.7.3 Truck Business 5.7.4 Production and Sales 5.8 QingLing Motors (Group) Co., Ltd. 5.8.1 Profile 5.8.2 Operation 5.8.3 Truck Business 5.9 Jiangling Motors Co., Group 5.9.1 Profile 5.9.2 Jiangling Holdings Limited 5.9.3 Production and Sales 5.9.4 Capacity Distribution 5.9.5 Developments 5.10 SAIC GM Wuling (SGMW) 5.10.1 Profile 5.10.2 Key Business 5.10.3 Production and Sales 5.10.4 Manufacturing Bases 5.11 SAIC-IVECO Hongyan 5.11.1 Profile 5.11.2 Heavy-duty Truck Business 5.11.3 Sales Goal for 2017 5.12 Hubei Tri-Ring Special Vehicle Co., Ltd. 5.12.1 Profile 5.12.2 Truck Business 5.12.3 Production and Sales 5.12.4 Developments 5.13 XCMG Automobile 5.13.1 Profile 5.13.2 Heavy-duty Truck Business 5.13.3 Capacity Distribution 5.14 GAC HINO Motors Co., Ltd. 5.14.1 Profile 5.14.2 Operation 5.14.3 Heavy-duty Truck Business 5.14.4 Production Capacity 5.15 Zhejiang Feidie Automobile Manufacturing Co., Ltd. 5.15.1 Profile 5.15.2 Truck Business 5.16 Baotou Bei Ben Heavy-Duty Truck Co., Ltd. 5.16.1 Profile 5.16.2 Heavy-duty Truck Business 5.17 Shanxi Dayun Automobile Manufacturing Co., Ltd 5.17.1 Profile 5.17.2 Truck Business List of Charts - Classification of Truck (Freight Vehicle) - Applications of Truck - Technology Introduction of Key Heavy Truck Manufacturers in China - Schedule for Implementation of China's Motor Vehicle National V Emission Standards - Comparison of China's National IV and V Emission Standards - Standards for Identifying Oversize and Overload of Highway Freight Vehicles (in 6-axle case) - Policies and Regulations on Commercial Vehicle Telematics - Survey on Truck Telematics at Home and Abroad - China's Truck Ownership, 2010-2021E - China's Truck Output, 2010-2021E - China's Truck Sales, 2010-2021E - China's Truck Output and Growth Rate by Product, 2016-2017 - China's Truck Sales and Growth Rate by Product, 2016-2017 - China's Monthly Truck Exports, 2016 - China's Monthly Truck Imports, 2016 - Sales Volume and Market Share of Top10 Truck Manufacturers in China, 2016-2017 - China's Complete Heavy Truck Output and Sales Volume, 2010-2021E - China's Incomplete Heavy Truck Output and Sales Volume, 2010-2021E - China's Semi-trailer Towing Vehicle Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Heavy Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Heavy Truck Enterprises in China, 2016-2017 - Sales Volume and Market Share of Top10 Semi-trailer Towing Vehicle Manufacturers in China, 2016-2017 - Sales Volume of Natural Gas Heavy Trucks in China, 2014-2021E - Major Natural Gas Heavy Truck Manufacturers in China - High-end Heavy Trucks Launched by Enterprises in China - China's Complete Medium Truck Output and Sales Volume, 2010-2021E - China's Incomplete Medium Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Medium Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Medium Truck Manufacturers in China, 2016-2017 - China's Complete Light Truck Output and Sales Volume, 2010-2021E - China's Incomplete Light Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Light Truck Manufacturers in China, 2016-2017 - Sales Volume and Market Share of Top10 Incomplete Light Truck Manufacturers in China, 2016-2017 - China's Complete Mini Truck Output and Sales Volume, 2010-2021E - China's Incomplete Mini Truck Output and Sales Volume, 2010-2021E - Sales Volume and Market Share of Top10 Complete Mini Truck Manufacturers in China, 2016-2017 - Automotive Industry Chain - Cost Structure of Truck Industry - Transmission Supply of Major Heavy Truck Manufacturers in China - China's Galvanized Sheet (Strip) Output and Sales Volume, 2010-2017 - China's (Shanghai) Galvanized Coil Price, 2014-2017 - China's Cold-rolled Thin Sheet Output and Sales Volume, 2010-2017 - China's (Shanghai, Tianjin, Guangzhou) Cold-rolled Coil Price, 2016-2017 - China's Natural Rubber Spot and Future Price, 2012-2017 - China's Investment in Fixed Assets, 2010-2017 - China's Investment in Real Estate Development, 2010-2017 - China's New Housing Start Area and Sales Area, 2005-2017 - China's Highway Freight Volume and Turnover, 2005-2017 - FAW Jiefang Automotive's Heavy Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Medium Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Light Truck Output and Sales Volume, 2010-2017 - FAW Jiefang Automotive's Mini Truck Output and Sales Volume, 2010-2017 - Main Natural Gas Trucks of FAW Jiefang Automotive - Main Truck Production Bases of FAW Group - Sinotruk's Revenue and Net Income, 2010-2016 - Sinotruk's Gross Margin, 2010-2016 - Sinotruk's Revenue Structure by Business, 2016 - Sinotruk's Heavy Truck Output and Sales Volume, 2010-2017 - Sinotruk's Medium Truck Output and Sales Volume, 2010-2017 - Sinotruk's Light Truck Output and Sales Volume, 2010-2017 - Sinotruk's Heavy Truck Product Family Genealogy - Sinotruk's Main Product Configuration - Dongfeng Motor's Revenue and Net Income, 2011-2016 - Dongfeng Motor's Gross Profit and Gross Margin, 2011-2016 - Dongfeng Motor's Revenue Breakdown by Business, 2015-2016 - Dongfeng Motor's Heavy Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Medium Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Light Truck Output and Sales Volume, 2010-2017 - Dongfeng Motor's Mini Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Dongfeng Motor - Beiqi Foton Motor's Revenue and Net Income, 2010-2016 - Beiqi Foton Motor's Gross Margin, 2010-2016 - Beiqi Foton Motor's Revenue Breakdown and Gross Margin by Business, 2014-2016 - Heavy Truck Output and Sales Volume of BAIC Group (Beiqi Foton Motor), 2010-2017 - Medium Truck Output and Sales Volume of BAIC Group (Beiqi Foton Motor), 2010-2017 - BAIC Group's Light Truck Output and Sales Volume, 2010-2017 - BAIC Group's Mini Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Beiqi Foton Motor - Capacity of Beijing Foton Daimler, 2016 - Main Heavy Trucks of Shaanxi Automobile Group - Shaanxi Automobile Group's Heavy Truck Output and Sales Volume, 2010-2017 - Shaanxi Automobile Group's Medium Truck Output and Sales Volume, 2010-2017 - Shaanxi Automobile Group's Light Truck Output and Sales Volume, 2010-2017 - JAC's Revenue and Net Income, 2010-2016 - JAC's Gross Margin, 2010-2016 - JAC's Revenue Structure and Gross Margin by Product, 2016 - JAC's Heavy Truck Output and Sales Volume, 2010-2017 - JAC's Medium Truck Output and Sales Volume, 2010-2017 - JAC's Light Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of JAC, 2016 - Hualing Xingma Automobile's Assets and Net Income, 2012-2016 - Hualing Xingma Automobile's Products Series - Hualing Xingma Automobile's Truck Output and Sales Volume, 2015-2016 - Hualing Xingma Automobile's Truck Sales at Home and Abroad, 2015-2016 - Qingling Motors' Revenue and Net Income, 2010-2016 - Qingling Motors' Gross Margin, 2010-2016 - Qingling Motors' Revenue Breakdown by Product, 2015-2016 - Qingling Motors' Heavy Truck Output and Sales Volume, 2010-2017 - Qingling Motors' Medium Truck Output and Sales Volume, 2010-2017 - Qingling Motors' Light Truck Output and Sales Volume, 2010-2017 - Jiangling Motors' Revenue and Net Income, 2010-2016 - Jiangling Motors' Gross Margin, 2010-2016 - Jiangling Motors' Revenue Structure by Product, 2015-2016 - Jiangling Motors' Light Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of Jiangling Motors, 2016 - Development History of SAIC GM Wuling - Main Trucks (Mini Trucks) of SAIC GM Wuling - SAIC GM Wuling's Mini Truck Output and Sales Volume, 2010-2017 - Distribution of SAIC GM Wuling's Production Bases - SAIC-IVECO Hongyan's Heavy Truck Output and Sales Volume, 2010-2017 - SAIC-IVECO Hongyan's Sales Target, 2017 - Main Heavy Trucks of Hubei Tri-Ring Special Vehicle - Hubei Tri-Ring Special Vehicle's Heavy Truck Output and Sales Volume, 2010-2017 - Hubei Tri-Ring Special Vehicle's Medium Truck Output and Sales Volume, 2010-2017 - Hubei Tri-Ring Special Vehicle's Light Truck Output and Sales Volume, 2010-2017 - XCMG Automobile's Heavy Truck Output and Sales Volume, 2010-2017 - Truck Capacity Distribution of XCMG Automobile, 2016 - GAC Hino Motors' Assets, Liabilities, and Revenue, 2012-2016 - GAC Hino Motors' Heavy Truck Output and Sales Volume, 2010-2017 - GAC Hino Motors' Capacity, 2016 - Zhejiang Feidie Automobile Manufacturing's Heavy Truck Output and Sales Volume, 2010-2017 - Zhejiang Feidie Automobile Manufacturing's Medium Truck Output and Sales Volume, 2010-2017 - Zhejiang Feidie Automobile Manufacturing's Light Truck Output and Sales Volume, 2010-2017 - Baotou Bei Ben Heavy-Duty Truck's Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Heavy Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Medium Truck Output and Sales Volume, 2010-2017 - Shanxi Dayun Automobile Manufacturing's Light Truck Output and Sales Volume, 2010-2017 - Truck Sales Growth in China, 2011-2021E - China's Truck Market Structure, 2010-2021E - Market Share of Top10 Truck Manufacturers in China, 2016 - Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO) - China Biologic Products, Inc. (NASDAQ: CBPO) - Green Cross China - Guizhou Taibang Biological Products Co., Ltd. - Hualan Biological Engineering,Inc. - Humanwell Healthcare Group Co., Ltd. - Jiangxi Boya Bio-Pharmaceutical Co., Ltd. - Shandong Taibang Biological Products Co., Ltd. - Shanghai Institute of Biological Products Co., Ltd. - Shanghai RAAS Blood Products Co., Ltd. - Shanxi Kangbao Biological Product Co., Ltd. - Shenzhen Weiguang Biological Products Co., Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. - Walvax Biotechnology Co, Ltd. - Xi'an Huitian Blood Products Co., Ltd. - Zhenxing Biopharmaceutical & Chemical Co., Ltd. For more information about this report visit http://www.researchandmarkets.com/research/2dng4t/china_blood Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-blood-product-industry-report-2017-product-market-size-expected-to-hit-rmb475-billion-in-2021---research-and-markets-300459175.html


BEIJING, May 20, 2017 /PRNewswire/ -- China Biologic Products, Inc. ("China Biologic" or the "Company") (NASDAQ: CBPO), a leading fully integrated plasma-based biopharmaceutical company in China, announced today that the Securities and Exchange Commission has declared effective a Form F-4 Registration Statement, which includes a Proxy Statement of China Biologic and also constitutes a Prospectus of China Biologic Products Holdings, Inc. (the "proxy statement/prospectus"), in connection with the proposed redomicile of China Biologic as a Cayman Islands company. The redomicile will be effected through a merger (the "Merger") of China Biologic with China Biologic Products Holdings, Inc., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of China Biologic, resulting in the shares of China Biologic being converted into the right to receive shares of China Biologic Products Holdings, Inc. The Company, with almost all of its current business and operations conducted outside of the United States, expects the Merger will improve its ability to grow both internationally and as well as in China which has a strictly regulated biopharmaceutical industry that may officially or unofficially favor companies that are incorporated in jurisdictions that are not politically and economically perceived to be in competition with China. Additionally, the proposed redomicile can result in a reduction in operational, administrative, legal and accounting costs over the long term. Holders of China Biologic common stock as of May 17, 2017, the record date, will be asked to approve the proposed Merger at the 2017 annual meeting of stockholders, to be held on Friday, June 30, 2017 at 10:00 a.m., Beijing time. Stockholders of record as of the close of business on the record date are entitled to notice of and vote at the annual meeting, which will be held at the Company's principal office located at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing 100125, People's Republic of China. China Biologic will commence the mailing of the proxy statement/prospectus to all holders of China Biologic common stock as of the record date on May 19, 2017. The proposed Merger is subject to approval by holders of China Biologic common stock. China Biologic Products, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its majority owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com. For more information, please contact: This release includes forward-looking statements, including statements regarding the terms and completion of the proposed Merger, the change in the Company's place of incorporation, the ability to grow internationally and in China, the reduction in operating expenses resulting therefrom, the proposal to be approved by the Company's stockholders at the annual meeting and the commencement of the mailing of the proxy statement/prospectus. These statements are forward-looking in nature and subject to risks and uncertainties that may cause actual results to differ materially. These uncertainties include, but are not limited to, the ability of the parties to consummate the proposed Merger, the satisfaction of closing conditions to consummate the Merger, the Company's ability to realize the anticipated reduction in operating expenses, and obtaining requisite approvals, including from the Company's stockholders. All forward-looking statements included in this release are based upon information available to the Company as of the date of this release, which may change, and we assume no obligation to update any such forward-looking statement. Additional Information and Where to Find It This communication is being made in respect of a proposed redomicile transaction. INVESTORS OF CHINA BIOLOGIC ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE MAKING A DECISION CONCERNING THE PROPOSED MERGER. These documents will contain important information that investors should consider. The proxy statement/prospectus will be mailed to China Biologic stockholders. The proxy statement/ prospectus and any other documents filed by China Biologic with the SEC may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by China Biologic by contacting China Biologic's Investor Relations by phone at +86-10-6598 3177 or by email at ir@chinabiologic.com. China Biologic and its respective officers and directors may be deemed to be participants in the solicitation of proxies in connection with the proposed Merger. Information regarding the interests of these directors and executive officers in the proposed Merger, if any, is included in the proxy statement/prospectus. You can find information about China Biologic's directors and executive officers in its proxy statements and Annual Reports on Form 10-K, previously filed with the SEC. Each of these documents is available free of charge at the SEC's web site at http://www.sec.gov and from China Biologic Investor Relations. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-biologic-announces-effectiveness-of-registration-statement-and-mailing-of-definitive-proxy-statementprospectus-for-2017-annual-meeting-of-stockholders-300460666.html


Hemophilia B Market: In-Depth Review of Drug Research Pipeline & Companies for the First Half of 2017 Albany, NY, May 17, 2017 --( Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068017 In the present scenario, the number of babies born with the hereditary bleeding disorder hemophilia B is on a sharp rise. This report begins with a holistic introduction of the hemophilia market, along with the overview of the developments in the therapeutics. Various new products and the ones under development in the pipeline are assessed with the focus on the top companies, universities and institutes, from this sector. Additionally, the research report analyzes the drug profiles using vital parameters such as product description, mechanism of action and the progress in research and development. These data on the drugs and treatments can be extremely resourceful to companies interested in this sector. The report similarly covers the useful reviews of the key players involved in the development of improved curative drugs for hemophilia B. It examines each drug profiles considering the stage of development, drug target, molecule type, route of administration, as well as the mechanism of action. Such valuable information from this report can help investors gain a stronger foothold in the hemophilia B industry. By analyzing the therapeutics under development in terms of the companies, universities and institutes, the study reveals more formidable facts. Moreover, the research report analyzes the latest scientific developments in the sector quite precisely. It reveals the results of the molecule development processes in companies during the stages such as pre-registration, phase III, phase II, phase I, as well as IND and CTA filed, preclinical and discovery. Correspondingly, the study renders similar facts about the preclinical and discovery stages within universities for the benefit of the buyer. Browse Full Report with TOC - http://www.marketresearchhub.com/report/hemophilia-b-pipeline-review-h1-2017-report.html In the concluding part of the report, analysts have carefully examined the companies involved in the development of premium therapeutics. Some of the leading companies active in this enterprising development are Alnylam Pharmaceuticals Inc, Amarna Therapeutics BV, Bayer AG, Bioverativ Inc, Catalyst Biosciences Inc, China Biologic Products Inc, CSL Ltd, Dimension Therapeutics Inc, Genethon SA and Green Cross Corp. From this evaluation about the leading players and the history of the product development, new entrepreneurs can definitely aim for higher revenues from this booming sector. About Market Research Hub Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Albany, NY, May 17, 2017 --( PR.com )-- Recently, the hemophilia B market is seeing a big surge due to increasing prevalence of the disorder- hemophilia B, sometimes known as the royal disease which affects people born without the blood clotting factor IX. To take advantage of this situation, a new report has been added to the vast online repository of Market Research Hub (MRH), and is titled "Hemophilia B - Pipeline Review, H1 2017." The research study analyzes the pharmacological and historical developments, alongside the latest news towards finding the best treatment for the disease, within this specific industry during the year 2017.Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068017In the present scenario, the number of babies born with the hereditary bleeding disorder hemophilia B is on a sharp rise. This report begins with a holistic introduction of the hemophilia market, along with the overview of the developments in the therapeutics. Various new products and the ones under development in the pipeline are assessed with the focus on the top companies, universities and institutes, from this sector. Additionally, the research report analyzes the drug profiles using vital parameters such as product description, mechanism of action and the progress in research and development. These data on the drugs and treatments can be extremely resourceful to companies interested in this sector.The report similarly covers the useful reviews of the key players involved in the development of improved curative drugs for hemophilia B. It examines each drug profiles considering the stage of development, drug target, molecule type, route of administration, as well as the mechanism of action. Such valuable information from this report can help investors gain a stronger foothold in the hemophilia B industry. By analyzing the therapeutics under development in terms of the companies, universities and institutes, the study reveals more formidable facts. Moreover, the research report analyzes the latest scientific developments in the sector quite precisely. It reveals the results of the molecule development processes in companies during the stages such as pre-registration, phase III, phase II, phase I, as well as IND and CTA filed, preclinical and discovery. Correspondingly, the study renders similar facts about the preclinical and discovery stages within universities for the benefit of the buyer.Browse Full Report with TOC - http://www.marketresearchhub.com/report/hemophilia-b-pipeline-review-h1-2017-report.htmlIn the concluding part of the report, analysts have carefully examined the companies involved in the development of premium therapeutics. Some of the leading companies active in this enterprising development are Alnylam Pharmaceuticals Inc, Amarna Therapeutics BV, Bayer AG, Bioverativ Inc, Catalyst Biosciences Inc, China Biologic Products Inc, CSL Ltd, Dimension Therapeutics Inc, Genethon SA and Green Cross Corp. From this evaluation about the leading players and the history of the product development, new entrepreneurs can definitely aim for higher revenues from this booming sector.About Market Research HubMarket Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Click here to view the list of recent Press Releases from Market Research Hub

Loading China Biologic Products collaborators
Loading China Biologic Products collaborators